(p < 0.05 for paclitaxel angioplasty vs. either control)

Slides:

Advertisements

Similar presentations

Stenting and Angioplasty with Protection in Patients at High-Risk for Endarterectomy Presented by Jay Yadav, MD on behalf of the SAPPHIRE Investigators.

Advertisements

Technical approach PCI in Small Vessels Washington Cardiology Center Augusto Pichard, L. Satler, K. Kent, R. Waksman, J. Laird, W. Suddath, J. Sharretts,

Upendra Kaul, MD for the TUXEDO INDIA Investigators Paclitaxel Eluting Versus Everolimus Eluting Stents in Patients with Diabetes Mellitus and Coronary.

A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.

Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis.

University of Modena and Reggio Emilia Vascular Surgery – Director: prof. Coppi Silingardi R. Veronesi J. Gennai S.

Remote SFA Endarterectomy

DRug Eluting Bbsorbable Metal Scaffold (DREAMS)

(p for noninferiority = 0.01)

Global Experience with Peripheral DCBs/Stent Studies: C.R. Bard

Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease Yiu Che Chan, MBBS, MD, FRCS, Stephen.

DCB for In-Stent Restenosis: Is It Superior to DES?

From: Paclitaxel-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal StentsThe TAXUS V ISR Randomized Trial JAMA. 2006;295(11):

NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.

Modern treatment of SFA

Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease Yiu Che Chan, MBBS, MD, FRCS, Stephen.

(CMR vs. guidelines, p < 0.001)

ISAR‐PEBIS (Paclitaxel‐Eluting Balloon Versus Conventional Balloon Angioplasty for In‐Stent Restenosis of Superficial Femoral Artery): A Randomized Trial.

Stenting of Coronary Arteries in Non Stress/Benestent Disease

Catheter-Based Treatment of Coronary Artery Disease

(p < for group 1 or 2 vs. group 3)

AcoArt I Trial design: Patients with femoropopliteal artery disease were randomized to paclitaxel-coated balloon angioplasty (n = 100) vs. standard peripheral.

Giuseppe Biondi Zoccai

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

TECAM Trial design: STEMI patients who underwent successful reperfusion therapy were randomized on day 1 to intracoronary bone marrow autologous mononuclear.

Angiography-guided PCI

BBK II Trial design: Patients undergoing a two-stent approach for a de novo bifurcation lesion were randomized in a 1:1 fashion to either culotte stenting.

Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease Yiu Che Chan, MBBS, MD, FRCS, Stephen.

EXCEL Trial design: Patients with unprotected left main disease were randomized to either PCI with an Xience everolimus-eluting stent (EES) or CABG. They.

American College of Cardiology Presented by Dr. Stephan Windecker

Losartan vs. Atenolol in Marfan Syndrome

Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.

FAIR Trial design: Patients with SFA in-stent restenosis (ISR) were randomized to either a paclitaxel-coated balloon (DCB) (dose 3.5 μg/mm2) or routine.

REALITY: 8 month results

CANOA Trial design: Patients undergoing percutaneous closure of an ASD with the Amplatzer Septal Occluder were randomized to aspirin 80 mg plus clopidogrel.

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

EXCITE ISR Trial design: Participants with femoropopliteal in-stent restenosis were randomized to excimer laser atherectomy + adjunctive angioplasty (n.

SMILE Trial design: NSTEMI patients were randomized to complete revascularization during the index procedure (i.e., 1-stage revascularization; n = 264)

TUXEDO–India Trial design: Patients with type 2 diabetes mellitus (DM2) and coronary artery disease undergoing PCI were randomized to receive Taxus Element.

Modified Rankin score 0-2

ATMOSPHERE Trial design: Patients with symptomatic heart failure were randomized in a 1:1:1 fashion to either aliskiren 300 mg once daily, enalapril 5.

EVERBIO II Trial design: Patients with CAD were randomized in a 1:1:1 fashion to either Absorb BVS, Biomatrix Flex stent [BES], or Promus Element EES.

ILLUMENATE Trial design: Patients with superficial femoral artery (SFA) and/or popliteal arterial stenoses were randomized in a 2:1 fashion to either balloon.

BASKET-PROVE II Trial design: Subjects with stable or unstable coronary artery disease undergoing stent implantation were randomized to a biodegradable-polymer.

Presented at ACC 2003 Late Breaking Clinical Trials

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

ZEUS Trial design: Patients who were deemed uncertain DES candidates due to bleeding, thrombotic, or restenosis risk were randomized to receive either.

(p = 0.32 for noninferiority)

Drug-eluting stents for in-stent restenosis

AMACING Trial design: Patients with chronic kidney disease undergoing intravascular iodinated contrast administration were randomized to prophylactic hydration.

(p < for noninferiority)

The Fall of Carotid Endarterectomy and Rise of Carotid Artery Stenting in Ontario from 2002 to 2014 Mohamad A. Hussain, Muhammad Mamdani, Gustavo Saposnik,

(p = for noninferiority)

CHAMPION Trial design: Patients with recent hospitalization for heart failure were implanted with a pulmonary artery pressure monitor and randomized so.

Long-term results of a multicenter randomized study on direct versus crossover bypass for unilateral iliac artery occlusive disease Jean-Baptiste Ricco,

SMART-STRATEGY Trial design: Patients with a bifurcation coronary lesion were randomized to a conservative strategy (n = 128) vs. an aggressive strategy.

ITALIC Trial design: Patients with Xience V (everolimus-eluting stent) PCI were randomized in a 1:1 fashion to receive 6 or 24 months of dual antiplatelet.

DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.

DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.

OPTIDUAL Trial design: Patients who received a drug-eluting stent and were event-free at 12 months were randomized to an additional 36 months of DAPT with.

IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.

MATRIX: Radial vs. Femoral

(p for non-inferiority < 0.001)

American College of Cardiology Presented by Dr. Adnan Kastrati

NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.

A 44-year-old male patient with symptomatic left intracranial vertebral artery stenosis treated with balloon predilation plus self-expanding stenting.

Angiographic image of the angioplasty-balloon-occluded left superficial femoral artery (SFA; left panel), which is partly filled with radiographic contrast.

Zoltán Ruzsa et al. JCIN 2018;11:

Presentation transcript:

(p < 0.05 for paclitaxel angioplasty vs. either control) ISAR-STATH Trial design: Patients with SFA disease were randomized to paclitaxel-eluting balloon angioplasty plus stenting (n = 48) vs. plain balloon angioplasty plus stenting (n = 52) vs. directional atherectomy with distal protection and bailout stenting (n = 55). Results (p < 0.05 for paclitaxel angioplasty vs. either control) Percent diameter stenosis at 6 months: 34% of the paclitaxel-eluting balloon angioplasty plus stenting group vs. 56% of the plain balloon angioplasty plus stenting group vs. 55% of the directional atherectomy with distal protection and bailout stenting group (p = 0.009 for paclitaxel-eluting balloon plus stent vs. plain balloon angioplasty plus stent group and p = 0.007 for paclitaxel-eluting balloon plus stent vs. directional atherectomy group) 56 55 % 34 Conclusions Among patients with symptomatic superficial femoral artery disease, paclitaxel-eluting balloon angioplasty plus stenting appeared to be superior to plain balloon angioplasty plus stenting or to directional atherectomy with distal embolic protection plus bailout stenting Paclitaxel angioplasty plus stent Plain angioplasty plus stent Directional atherectomy with distal protection Ott I, et al. Circulation 2017;135:2218-26